Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Technically, the stock approaches a strong medium-term resistance at JPY 1767.
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ASTELLAS PHARMA INC.5.71%30 155
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159
ABBVIE INC.3.46%195 720
ELI LILLY AND COMPANY22.09%186 883
NOVO NORDISK A/S4.18%168 128
AMGEN INC.10.26%147 580
BRISTOL-MYERS SQUIBB COMPAN..4.08%145 890
ASTRAZENECA PLC6.19%139 483
SANOFI3.51%124 582
GLAXOSMITHKLINE PLC2.85%94 107
JIANGSU HENGRUI MEDICINE CO..1.02%92 231
CHUGAI PHARMACEUTICAL CO., ..2.11%88 992
More Results
Financials
Sales 2021 1 272 B 12 263 M 12 263 M
Net income 2021 181 B 1 746 M 1 746 M
Net cash 2021 440 B 4 242 M 4 242 M
P/E ratio 2021 17,0x
Yield 2021 2,50%
Capitalization 3 130 B 30 155 M 30 178 M
EV / Sales 2021 2,11x
EV / Sales 2022 1,93x
Nbr of Employees 15 883
Free-Float 99,2%
Upcoming event on ASTELLAS PHARMA INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes